Table 1.

Comparison of baseline characteristics: terlipressin vs midodrine plus octreotide

Variable description	Statistic or category	CBPS adjusted			Unadjusted
		Midodrine and octreotide (N = 55)	Terlipressin (N = 89)a	P value	Midodrine and octreotide (N = 55)	Terlipressin (N = 159)	P value
Age	Mean (SD)	58.04 (11.40)	58.09 (13.31)	0.976	58.04 (11.40)	56.22 (10.25)	0.296
	Median (Q1–Q3)	61.13 (49.50–66.04)	60.32 (51.82–65.75)		61.13 (49.50–66.04)	57.44 (50.00–64.26)
	Range	30.00–76.00	28.11–77.96		30.00–76.00	28.11–77.96
Sex, %	Female	41.82	45.89	0.633	41.82	42.77	0.902
	Male	58.18	54.11		58.18	57.23
Race, %	American Indian or Alaskan Native	0.00	0.44	<0.001	0.00	1.27	0.002
	Asian	7.27	1.12		7.27	1.27
	Black or African American	10.91	3.34		10.91	4.46
	Hispanic or Latino	12.73	14.34		12.73	12.10
	White	63.64	80.76		63.64	80.89
	Unknown	5.45	0.00		5.45	0.00
Listed for transplant at baseline, %	Yes	9.09	25.93	0.013	9.09	25.16	0.012
Baseline SCr, mg/dL	Mean (SD)	2.68 (0.79)	2.73 (0.57)	0.631	2.68 (0.79)	3.19 (0.67)	<0.001
	Median (Q1–Q3)	2.50 (2.01–3.21)	2.58 (2.33–2.90)		2.50 (2.01–3.21)	3.09 (2.63–3.62)
	Range	1.66–4.94	1.90–4.90		1.66–4.94	1.90–4.90
Baseline SCr (categorical), %	<3.0 mg/dL	69.09	75.60	0.339	69.09	44.65	0.002
	≥3.0–<5.0 mg/dL	30.91	24.40		30.91	55.35
Baseline MELD score	Mean (SD)	29.93 (5.52)	29.74 (6.97)	0.845	29.93 (5.52)	30.21 (6.01)	0.744
	Median (Q1–Q3)	30.24 (25.99–34.22)	29.34 (25.08–33.16)		30.24 (25.99–34.22)	29.93 (24.98–34.28)
	Range	15.96–42.25	16.00–40.00		15.96–42.25	16.00–40.00
Baseline MELD cohort (categorical), %	<34	72.73	74.35	0.823	72.73	67.30	0.454
	≥34	27.27	25.65		27.27	32.70
ACLF, %	0	5.45	2.59	0.672	5.45	0.63	0.047
	1	52.73	58.91		52.73	62.89
	2	41.82	38.50		41.82	36.48
Encephalopathy	Grade 0–1	83.64	83.47	0.998	83.64	79.87	0.743
	Grade 2	14.55	14.83		14.55	18.87
	Grade 3	1.82	1.71		1.82	1.26
Baseline bilirubin, mg/dL	Mean (SD)	9.81 (9.00)	9.23 (15.63)	0.736	9.81 (9.00)	8.33 (9.77)	0.303
	Median (Q1–Q3)	5.75 (2.58–14.55)	4.79 (2.31–10.70)		5.75 (2.58–14.55)	4.23 (2.12–9.20)
	Range	0.30–33.90	0.30–43.70		0.30–33.90	0.30–43.70
Baseline Child-Pugh	Class A (5–6)	1.82	1.44	0.306	1.82	2.52	0.133
	Class B (7–9)	21.82	34.90		21.82	38.36
	Class C (10–15)	74.55	59.96		74.55	56.60
Baseline MAP, mm Hgb	Mean (SD)	78.71 (12.64)	77.30 (14.24)	0.548	78.71 (12.64)	77.39 (12.48)	0.565
	Median (Q1–Q3)	74.75 (71.63–88.38)	77.17 (68.76–84.00)		74.75 (71.63–88.38)	77.06 (68.67–83.88)
	Range	51.00–111.30	49.00–117.67		51.00–111.30	49.00–117.67
Baseline INR cohort	<2.5	83.64	85.72	0.731	83.64	85.53	0.734
	≥2.5	16.36	14.28		16.36	14.47
Total exposure of concomitant albumin, g	Mean (SD)	281.04 (316.31)	204.59 (215.36)	0.10	281.04 (316.31)	218.74 (185.49)	0.17
	Median (Q1–Q3)	181.25 (104.69–303.13)	161.01 (83.04–245.25)		181.25 (104.69–303.13)	167.19 (89.84–260.94)
	Range	12.50–1,725.00	25.00–1,312.50		12.50–1,725.00	25.00–1,312.50
Duration of concomitant albumin, d	Mean (SD)	5.40 (4.85)	4.33 (4.06)	0.146	5.40 (4.85)	4.51 (3.43)	0.214
	Median (Q1–Q3)	3.21 (2.06–5.63)	3.03 (1.70–4.79)		3.21 (2.06–5.63)	3.15 (1.65–5.28)
	Range	1.00–28.00	1.00–20.00		1.00–28.00	1.00–20.00
ICU admission before or during treatment, %	Yes	56.36	16.12	<0.001	56.36	16.98	<0.001
Total treatment duration, d	Mean (SD)	6.24 (5.04)	6.62 (4.95)	0.622	6.24 (5.04)	7.02 (4.57)	0.309
	Median (Q1–Q3)	3.83 (2.06–9.25)	4.89 (3.21–8.05)		3.83 (2.06–9.25)	5.23 (3.32–8.60)
	Range	2.00–26.00	1.00–25.00		2.00–26.00	1.00–25.00

ACLF, acute-on-chronic liver failure; HRS, hepatorenal syndrome; ICU, intensive care unit; INR, international normalized ratio; MAP, mean arterial pressure; MELD, model for end-stage liver disease; RRT, renal replacement therapy; SCr, serum creatinine.

^aN = 89 is the effective sample size for the terlipressin cohort after CBPS reweighting.

^bBaseline MAP for the midodrine and octreotide cohort was evaluated based on 67.3% (37/55) patients with nonmissing value in the chart review data.